SGLT2 Inhibitors and Their Role in Lowering Heart Failure Risk in Type 2 Diabetes Mellitus

Summary:
Sodium–glucose cotransporter-2 (SGLT2) inhibitors have significantly improved the management of Type 2 Diabetes Mellitus by not only controlling blood glucose but also benefiting blood pressure, weight, and kidney function. Evidence from large trials and a systematic review of six high-quality randomized studies involving over 47,000 participants shows that these drugs reduce the risk of Heart Failure hospitalization by 28%, with consistent results across studies. The benefit was observed across multiple agents, including empagliflozin, canagliflozin, dapagliflozin, and sotagliflozin, reinforcing SGLT2 inhibitors as an important strategy for heart failure prevention in clinical practice. 

Sodium–glucose cotransporter-2 (SGLT2) inhibitors have transformed the treatment approach for type 2 diabetes mellitus (T2DM) by enhancing blood glucose control while also providing favorable effects on blood pressure, body weight, and kidney function. Findings from large cardiovascular outcome trials have consistently demonstrated their ability to lower the risk of hospitalization for heart failure (HHF), irrespective of patients’ initial cardiovascular risk profiles.

A systematic review and meta-analysis assessed the effectiveness of SGLT2 inhibitors in reducing HHF among individuals with T2DM and examined whether these benefits were uniform across different agents. The study adhered to PRISMA guidelines and Cochrane standards, with inclusion criteria structured according to the PICO framework. To address variability between studies, a random-effects model using the Mantel–Haenszel approach was employed.

Six randomized controlled trials conducted between 2015 and 2021 were analyzed, involving a total of 47,411 participants, of whom 26,262 received SGLT2 inhibitors and 21,149 served as controls. Overall, the studies were of high quality, with a low risk of bias across major assessment domains.

The combined results showed a significant decrease in HHF risk associated with SGLT2 inhibitor use (RR 0.72; 95% CI: 0.65–0.80; p<0.00001), reflecting a 28% relative risk reduction. Heterogeneity among the studies was low (I² = 4.5%), indicating strong consistency in the findings.

Subgroup analyses revealed significant reductions in HHF risk across individual medications, including empagliflozin (RR 0.65), canagliflozin (RR 0.61), dapagliflozin (RR 0.74), and sotagliflozin (RR 0.69), each demonstrating clinically meaningful benefits, though with some variation in effect size.

Overall, the findings highlight that SGLT2 inhibitors substantially reduce the risk of HHF in patients with T2DM, with consistent effects observed across different agents. These results underscore their importance as a central therapeutic option for preventing heart failure and support their wider use in clinical practice.